130 related articles for article (PubMed ID: 12550114)
1. The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma.
Chana JS; Grover R; Tulley P; Lohrer H; Sanders R; Grobbelaar AO; Wilson GD
Br J Plast Surg; 2002 Dec; 55(8):623-7. PubMed ID: 12550114
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
3. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
4. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of c-myc oncogene expression in melanomas of the scalp.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Br J Plast Surg; 1998 Apr; 51(3):191-4. PubMed ID: 9664877
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
7. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.
Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891
[TBL] [Abstract][Full Text] [Related]
8. The prognostic importance of c-myc oncogene expression in head and neck melanoma.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Ann Plast Surg; 2001 Aug; 47(2):172-7. PubMed ID: 11506326
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma.
Husain Z; FitzGerald GB; Wick MM
J Invest Dermatol; 1990 Nov; 95(5):571-5. PubMed ID: 2121834
[TBL] [Abstract][Full Text] [Related]
10. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
11. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.
Chana JS; Wilson GD; Cree IA; Alexander RA; Myatt N; Neale M; Foss AJ; Hungerford JL
Br J Ophthalmol; 1999 Jan; 83(1):110-4. PubMed ID: 10209447
[TBL] [Abstract][Full Text] [Related]
12. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
Robinson LA; Smith LJ; Fontaine MP; Kay HD; Mountjoy CP; Pirruccello SJ
Ann Thorac Surg; 1995 Dec; 60(6):1583-91. PubMed ID: 8787447
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of SK-MEL-30 human melanoma cells by antisense c-myc oligonucleotides delivered by poly(N-isopropylacrylamide)/ poly(ethyleneimine) copolymer.
Dinçer S; Oskay EK; Piskin AK; Zeybek ND; Pişkin E
J Tissue Eng Regen Med; 2010 Jun; 4(4):284-90. PubMed ID: 19967748
[TBL] [Abstract][Full Text] [Related]
14. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.
Stewart DA; Xu X; Thomas SD; Miller DM
Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846
[TBL] [Abstract][Full Text] [Related]
15. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
[TBL] [Abstract][Full Text] [Related]
17. Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation.
Stewart DA; Thomas SD; Mayfield CA; Miller DM
Nucleic Acids Res; 2001 Oct; 29(19):4052-61. PubMed ID: 11574688
[TBL] [Abstract][Full Text] [Related]
18. Use of oncogene expression as an independent prognostic marker for primary melanoma.
Grover R; Pacifico MD; Wilson GD; Sanders R
Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
[TBL] [Abstract][Full Text] [Related]
20. Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma.
Utikal J; Leiter U; Udart M; Kaskel P; Peter RU; Krähn GM
Cancer Invest; 2002; 20(7-8):914-21. PubMed ID: 12449722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]